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Antibodies directed against the b chain of the T cell receptor (anti-Vb antibodies) are useful to identify the Vb
repertoire of T cells in various diseases and to quantify numbers of Vb-bearing T cells. The goals of this study were
to identify Vbþ cases of leukemic phase cutaneous T cell lymphoma (CTCL) and to compare the percentage of
positive calls with other measures of blood tumor burden, i.e., lymphocyte subsets with a CD4þCD7 and
CD4þCD26 phenotype and Se´zary cell counts. Thirty-three of 49 (67%) cases of leukemic CTCL reacted with an
anti-Vb antibody. When combined with reports from the literature, the frequency of Vb5 (probably Vb5.1) usage was
relatively high when compared with Vb2 that is also frequently expressed by normal CD4þ T cells. The percentage
of Vbþ cells correlated to the percentage of CD4þCD7 and CD4þCD26 cells for cases in which the neoplastic
cells were deﬁcient in expression of CD7 and CD26, respectively, but not the Se´zary cell count. We hypothesize that
the increased Vb5.1 usage in CTCL may be the result of depletion of Vb2 and other Vb-bearing T cells by
staphylococcal superantigens prior to neoplastic transformation, resulting in a relative increase in the frequency of
Vb5.1 usage in CTCL.
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Cutaneous T cell lymphoma (CTCL) is a clonal expansion of
skin-associated neoplastic T cells that typically express a T
cell receptor (TCR)abþCD3þCD4þCD8 immunopheno-
type (Kim and Hoppe, 1999). The two major clinical subsets
of CTCL are mycosis fungoides (MF) and Se´zary syndrome
(SS). MF is characterized clinically by the sequential pro-
gression from patch to plaque to tumor phases, a distinc-
tion based on the degree of cellular infiltration at lesion sites
in the skin. SS is characterized by generalized erythroderma
and ‘‘leukemic’’ blood involvement (Vonderheid et al, 2002).
SS may develop de novo as erythroderma or be preceded
by pruritus alone, non-specific dermatitis, or skin manifes-
tations typical for MF.
Recently, the International Society for Cutaneous Lymph-
omas (ISCL) proposed five hematologic criteria to define
leukemic blood involvement that may occur in SS and less
often advanced MF, herein referred to as the leukemic
phase of CTCL (Vonderheid et al, 2002). These are: (1) an
absolute Se´zary cell count of 1.0 K per mL or more; (2) an
increase in CD3þ or CD4þ T cells in the blood resulting in
a CD4/CD8 ratio of 10 or more; (3) an increase in T cells with
an aberrant phenotype; (4) relative or absolute lymph-
ocytosis with molecular genetic evidence of a dominant T
cell clone; and (5) a chromosomally abnormal T cell clone in
the blood. Since the ISCL criteria were published, two ad-
ditional hematologic criteria based on the percentage of
CD4þ lymphocytes that are deficient in surface expression
of CD7 or CD26 have been proposed to represent leukemic
involvement, specifically CD4þCD7 and CD4þCD26
percentages of 40% and 30% or more, respectively (Berne-
ngo et al, 2001; Vonderheid and Bernengo, 2003). Antibod-
ies directed against the alpha or beta chains of the TCR also
have been used clinically to quantify neoplastic T cells in the
blood (Vonderheid et al, 1994; Scala et al, 2002; Schwab
et al, 2002; Ferenczi et al, 2003; Michel et al, 2003), but the
criteria that differentiates leukemic involvement in CTCL
from a lesser magnitude of blood involvement or from
benign erythrodermas have not been established.
The human TCR beta V region (TRVB) locus comprises
about 65 TRVB gene segments located on chromosome 7
at band 7q34. In 1999, under the auspices of the Human
Genome Organization (HUGO) Nomenclature Committee,
the classification system proposed by Rowen (Rowen et al,
1996) was adopted as the standardized nomenclature (for
additional information, see IMGT, the international ImMuno-
Gene Tics information system; http://imgt.cines.fr (Initiator
and coordinator: Marie-Paule Lefranc, Montpellier, France)).
Of the TRVB gene elements, 39–47 genes qualify as func-
tional TRVB genes that belong to 23 Vb families. TheStudies performed in Philadelphia, PA, USA.
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number of functional genes for each Vb family ranges from a
single gene in 16 families up to five genes in the Vb5 family,
six genes in the Vb7 family, and seven genes in the Vb6
family.
Vb usage by peripheral T cells is not proportional to the
number of functional genes in each Vb family, but is deter-
mined primarily in the thymus (Sprent and Webb, 1995).
Double-positive CD4þCD8þ thymocytes that receive a
low level stimulation mature into CD4þ or CD8þ via stim-
ulation of the TCR in consort with CD4 or CD8 that mediate
contact with class II or class I MHC, respectively. Cells that
receive no stimulation or a high level of stimulation against
self-MHC-peptides undergo clonal deletion; this is the fate
of more than 95% of thymocytes. Because of the close
similarity between thymic epithelial cells and keratinocytes
(Patel et al, 1995), the skin has been implicated in peripheral
selection of T cells in both atopic dermatitis (AD) and CTCL
(Haynes et al, 1982; Mastrandrea et al, 1998). Post-thymic
events such as selective stimulation of certain Vb sequenc-
es by superantigens (SAg) further modify the Vb repertoire
of peripheral T cells.
In normal peripheral blood, certain Vb families predom-
inate in the T cell repertoire, e.g., Vb2, Vb4, Vb6, and Vb13,
whereas others are rarely used, e.g., Vb10 and Vb18 (Choi
et al, 1989; Gorski et al, 1994; Hall and Lanchbury, 1995;
Gran et al, 1998). It is thought that differences in reactivity
between MHC molecules and Vb segments in the thymus
influences the Vb repertoire of CD4þ and CD8þ cells, and
that this accounts for the increased expression of Vb2,
Vb5.1, Vb6.7, Vb8, and Vb12 on CD4þ cells compared with
CD8þ cells (Grunewald et al, 1991; Geneve´e et al, 1994;
Reed et al, 1994; Shigematsu et al, 1996; van den Beemd
et al, 2000).
Commercially available monoclonal antibodies currently
cover more than 80% of the TCR Vb repertoire (van den
Beemd et al, 2000). It is now possible for some of these
antibodies labeled with different chromophores to be mixed
together and used for rapid screening of suspect T cell
lymphoproliferations and immunodeficiency (Langerak et al,
2001; Pilch et al, 2002; Beck et al, 2003; Lima et al, 2003).
Of relevance to this report that deals with the use of anti-Vb
antibodies to assess Vb usage in a CD4þ malignancy, van
den Beemd et al (2000) found that the frequency of Vb5.1
expression on normal CD4þ T cells (median, 7.5%) is
second only to Vb2 (median, 9.2%) followed by Vb13.1-3
(median, 6.1%), Vb17 (median, 5.4%), and Vb8.1-2 (median,
5.1%).
SAg, when presented by MHC class II molecules on ac-
cessory or target cells such as keratinocytes (Travers et al,
2001), bind to T cells that bear certain Vb segments, result-
ing in stimulation and proliferation of 10 to 100 times the
number of CD4þ and CD8þ T cells that can be activated
by conventional antigens (Kotzin et al, 1993). This produces
a polyclonal expansion of different portions of the T cell
repertoire that eventually may be followed by anergy and/or
deletion of the stimulated cells (McCormack et al, 1993;
Miethke et al, 1995; Renno et al, 1995; Sprent and Webb,
1995). In this paper, we present evidence that Vb usage in
leukemic phase of CTCL is skewed toward Vb5.1, and hy-
pothesize that this biased usage might be the consequence
of the relative depletion of other Vb-bearing skin-homing T
cells (negative selection) through the sustained action of
skin microbial SAg prior to malignant transformation.
Results
The cases were categorized into three groups based on the
observed pattern of Vb antibody reactivity (Table S1). Group
1 consists of patients whose neoplastic cells reacted to a
single Vb antibody in the screening panel (defined as 20%
or more positive lymphocytes), and this was observed in 21
of the 42 (50%) samples including 5 previously studied pa-
tients with a known Vb sequence by RT-PCR and corre-
sponding anti-Vb antibody reactivity. In one previously
studied patient whose cells were shown to be Vb14
positive by RT-PCR and sequence analysis, 59% of the
neoplastic cells reacted with the anti-Vb5.1 antibody,
IMMU157, but not with the anti-Vb14 antibody, CAS1.1.3
(Bigler et al, 1996). This demonstrates that false positive
reactions may occasionally occur with Vb-specific antibod-
ies. The neoplastic cells of the remaining patients reacted
with antibodies directed against Vb5 (9 patients), as well
as Vb1 (1 patient), Vb3 (2 patients), Vb6.7 (1 patient), Vb8
(1 patient), Vb12 (3 patients), Vb13.6 (2 patients), and Vb23
(1 patient). When combined with the findings of 7 patients
previously characterized with anti-Vb antibodies (Table S1,
additional group), the neoplastic cells of nine of 13 anti-
Vb5-positive cases reacted with anti-Vb5.1 antibody (IM-
MUN157), three cases reacted with an anti-Vb5.2-3 anti-
body (MH3-2 or 1C1), and the cells of one patient reacted
with both anti-Vb5.2-3 (MH3-2) and anti-Vb5.2 (36213).
Group 2 consists of 12 samples that had ambiguous re-
sults with reactivity to more than one anti-Vb antibody in the
screening panel: six cases reacted to two antibodies, five
cases reacted to three antibodies, and one case had pos-
itive reactions to six antibodies. The appropriate Vb seg-
ment could be assigned from previous RT-PCR analysis in
two patients and repeat testing or studies on different sam-
ples clarified the results with three other cases. Thus, the Vb
expression on the neoplastic cells could be reliably as-
signed to five cases, but the other seven cases remain
uncertain.
It should be noted that 24%–87% of the neoplastic cells
from all seven unclassified samples reacted to an antibody
with Vb5 specificity (six samples, Vb5.1/clone IMMU157;
one sample, Vb5.2-3/clone MH3-2), and 40%–74% of the
cells from 5 samples also reacted with anti-Vb23 (clone
AHUT7). Although non-specific reactivity related to poor
preservation of the cells could explain these results (Beck
et al, 2003), this seems unlikely because other Vb antibodies
were typically non-reactive. The possibility that the anti-
Vb5.1 clone IMMU157 used in the screening panel was
yielding a falsely positive reaction must also be considered,
especially since a high percentage of cases in Group 1 were
positive to this antibody. In most instances, however, other
antibodies with Vb5.1 specificity confirmed the results. We
suspect that the anti-Vb23 clone AHUT7 may have reacted
inappropriately under conditions that we used for screening,
and that many of the unclassified samples are truly ex-
pressing a Vb5.1 segment. Finally, cross-reactivity of these
antibodies or co-expression of Vb5.1 and Vb23 (or other Vb
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segments) by neoplastic cells cannot be excluded, an in-
teresting possibility considering that approximately 1% of
normal T cells express two Vb chains (Davodeau et al, 1995;
Padovan et al, 1995). Repeat staining using different anti-
bodies, additional samples or molecular analysis will be
required to clarify these results.
Group 3 consisted of nine samples that did not react to
any of the anti-Vb antibodies in the screening panel. In most
cases the percentage of anti-Vb-positive cells in the screen-
ing panel was less than 1%, suggesting that the number of
normal Vb-bearing cells in the lymphocyte population was
depressed by non-reactive neoplastic cells. Included in this
group were three samples for which the Vb sequence had
been identified by RT-PCR. In two of these cases, the cells
did not react to the anti-Vb antibody corresponding to the
known Vb segment, as previously observed (Bigler et al,
1996). The other case was not tested using the appropriate
anti-Vb18 antibody.
Vb usage in leukemic phase CTCL Altogether, including
six previously characterized cases with a Vb antibody-pos-
itive clone, 33 of 49 (67%) of patients with leukemic CTCL
studied at our center were identified as having a neoplastic
cell population that reacted with an anti-Vb antibody. (Table
S1). An additional three patients with a known Vb sequence
by PCT (Vb5.2-3, Vb18, Vb20) but unconfirmed by an anti-
Vb antibody increases the total percentage of Vb-positive
clones to 36 (73%). The frequency of Vb usage of leukemic
phase CTCL was highest for Vb5 (14/36 or 39%) followed by
Vb3, Vb12, and Vb13.6 (3 patients each); Vb6.7, Vb8, and
Vb23 (2 patients), and single instances of Vb1, Vb7, Vb14,
Vb18, Vb20, Vb21.3, and Vb22.
Our findings, when combined with 136 reports from the
literature (Table S2; Fig S1), indicate that Vb5 gene segment
usage occurs in about 26% (44 of 172) of patients with
leukemic phase CTCL followed by Vb8 and Vb13 (about
10% each). The frequency of Vb5 usage in these cases
appears to be unusually high when compared with the fre-
quency of Vb usage by normal peripheral blood lymph-
ocytes for which the expression of Vb2, Vb4, Vb6, and Vb13
is even more frequent (Robinson, 1992; Gorski et al, 1994;
Gran et al, 1998). Considering that leukemic CTCL is a
CD4þ neoplasm and that Vb5.1 and Vb2 are the most fre-
quent Vb segments expressed on normal CD4þ cells, the
difference between the frequency of Vb5.1 per se and Vb2
usage in leukemic cases when both were studied (23 of 124
cases or 19% vs six of 124 cases or 5%, respectively) is
noteworthy.
To assess whether the observed frequency of Vb usage
in leukemic phase CTCL is skewed, the mean percentages
of Vb expression on normal CD4þ cells as determined by
anti-Vb antibodies (based on data on 85 normal specimens
provided by Beckman Coulter, Fullerton, California) was
used to calculate the expected frequency (number of cases)
that might be expected if neoplastic transformation oc-
curred randomly within the T cell population (Fig 1). The
mean values for Vb5.1, Vb5.2 and Vb5.3; Vb7.1 and Vb7.2;
and Vb13.1, Vb13.2, and Vb13.6 were added together for
the calculation, whereas Vb4, Vb6, Vb10, Vb15, and Vb19
were excluded. The distribution between observed and ex-
pected Vb usage was significantly different (Pearson’s w2
test, po0.001). The observed frequency of Vb5 was in-
creased and of Vb2 and Vb9 was decreased compared with
the expected (Fig 1). Whether Vb5.1 per se is significantly
increased over the expected could not be addressed, but it
should be noted that unlike Vb5.2-3, Vb5.1 usage appears
to decrease on normal CD4þ cells with aging (van den
Beemd et al, 2000). Considering that leukemic CTCL tends
to occur in older people and that the distribution of different
Vb families on CD4þ T cells in normal individuals seems
fairly stable throughout life (Cossarizza et al, 1995), one
might expect an even lower expected frequency of Vb5 us-
age than was reflected by use in our calculations of all age
ranges.
Correlation of Vb expression with other markers of
blood tumor burden The percentage of Vb-positive lymph-
ocytes was correlated to the percentage of CD4þCD7 and
CD4þCD26 lymphocyte subsets by flow cytometry, and
the number of Se´zary cells per 100 lymphocytes on blood
smears obtained at the same time as the blood sample for
antibody studies. (Table S1) Although not specific for neo-
plastic cells, these parameters have been utilized to measure
blood tumor burden in CTCL, and to differentiate erythroder-
mic CTCL from benign erythrodermas (Bernengo et al, 2001;
Vonderheid et al, 2002; Vonderheid and Bernengo, 2003).
The percentage of Vb antibody-positive cells in our pa-
tients ranged from 28% to 97% (n, 33; median, 67%;
mean  SD, 65%  21%). The percentage of Vb-positive
cells followed a normal distribution, suggesting that the
sampling was representative (Kolmogorov–Smirnov normal-
ity test, p40.2). The percentage of CD4þCD7 cells var-
ied from 0.8% to 92.7% (n, 30; median, 42%; mean  SD,
Figure1
Vb5 expression is increased in leukemic CTCL. The observed fre-
quency of Vb usage in patients with leukemic cutaneous T cell lymph-
oma reported the literature and this series (black bars) is significantly
different from the calculated expected frequency derived from mean
percentages of normal Vb family usage by CD4þ Tcells (hatched bars).
Asterisks signify the Vb families that appear to be significantly in-
creased (Vb5, p¼ 0.003) or decreased (Vb2, p¼ 0.027; Vb9, p¼ 0.002)
when tested against other Vb segments using Fisher’s exact test.
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45%  32%), the percentage of CD4þCD26 cells varied
from 0.3% to 98.7% (n, 30; median, 53%; mean  SD,
51%  34%), and the percentage of Se´zary cells on smears
ranged from 11% to 91% (n, 33; median, 41%; mean  SD,
46%  22%). The median values for the percentage of Vbþ
cells was significantly higher than the percentage of
CD4þCD7 cells (M-W, p¼0.02) and the Se´zary cell
count (M-W, p¼0.002), but not for CD4þCD26 (M-W,
p¼0.160) (Fig 2). The higher values for Vbþ cells com-
pared with the percentage of CD4þCD7, but not
CD4þCD26 cells, could reflect the contribution of
CD8þVbþ cells in the sample (unlikely due to the selec-
tion of cases with high CD4/CD8 ratios) (Lima et al, 2003),
and/or the fact that CD7 is less likely to be deficient on
neoplastic T cells than CD26 (most likely explanation)
(Bernengo et al, 2001; Vonderheid and Bernengo, 2003).
The difference between the percentage of Vbþ cells and
the Se´zary cell count likely reflects the fact that Se´zary cells
tend to be undercounted by visual inspection on smears,
especially when they are of small size (Heald et al, 1994).
A weakly positive, but statistically significant correlation
was found between the percentage of Vbþ cells and
CD4þCD7 cells in these samples (n, 30; r¼0.370, p¼
0.044), but not the percentage of CD4þCD26 cells (n, 30;
r¼0.275, p¼ 0.140). (Fig S2) These correlations, however,
are misleading because the neoplastic cells of CTCL are not
always deficient for CD7 or CD26 expression. Indeed, CD7
will be expressed at normal or near normal levels on the
neoplastic cells in about 30%–40% of patients with leu-
kemic phase CTCL (Vonderheid et al, 2001; Vonderheid and
Bernengo, 2003), and the same applies for CD26 albeit for a
smaller proportion of cases (Bernengo et al, 2001; Vonder-
heid and Bernengo, 2003). Thus, the strength of the corre-
lation of Vb positivity with either the CD4þCD7 or
CD4þCD26 subset in any series of leukemic patients
will be influenced by the number of cases in the series with
neoplastic cells expressing CD7 or CD26, respectively. The
admixture of CD7þ and CD7 cases and CD26þ and
CD26 cases may also underlie the observed lack of cor-
relation between the percentage of CD4þCD7 and
CD4þCD26 cells (n, 30; r¼ 0.231, p¼0.218).
In this series, CD7 and CD26 were expressed on more
than 50% of CD4þ lymphocytes in 14 of 30 (47%) and
eight of 30 (27%), respectively. To be clinically useful for
distinction from normal cells, most of which express CD7
and CD26 (Bernengo et al, 2001; Jones et al, 2001), a con-
siderable proportion of the neoplastic cells must show de-
ficient expression of CD7 or CD26. If the 16 cases with
deficient expression of CD7 on CD4þ cells are analyzed,
then a stronger correlation between Vbþ cells and
CD4þCD7 becomes apparent (r¼0.675, p¼0.004).
Similarly, the correlation between Vbþ cells and
CD4þCD26 for the 22 cases in which CD26 is expressed
on less than 50% of the CD4þ cells now becomes highly
significant (r¼0.824, po0.001).
Another way to express this is to correlate Vbþ cells to
either CD4þCD7 or CD4þCD26 cells, whichever is
highest, based the assumption that CD26 may be deficient
on CD7þ cases and vice versa. (Fig 3) Only two of our
patients had neoplastic cells that expressed both CD7 and
CD26 on most cells. If such an analysis is performed on our
samples, a strong positive correlation is observed (n, 30;
r¼0.594, po0.001). These observations demonstrate that
Vb expression on neoplastic cells correlates well with other
antibody-based measures of blood tumor burden in CTCL,
provided the appropriate phenotype of the neoplastic cells
is used, i.e., cells that are deficient for CD7 or CD26.
Finally, no correlation was found between Se´zary cell
counts and the percentages of Vb-positive cells (n, 33;
r¼0.122, p¼ 0.496), CD4þCD7 cells (n, 30; r¼ 0.175,
p¼0.350), nor CD4þCD26 cells (n, 30; r¼0.148,
p¼0.432). Even if the maximum percentage of
CD4þCD7 or CD4þCD26 for each case was used,
the correlation with Se´zary cell counts remained poor (n, 30;
r¼0.264, p¼ 0.157). A weak correlation between Se´zary
cell counts and the percentage of Vb-positive cells was also
found for 44 patients with leukemic CTCL reported in the
literature (r¼ 0.093, p¼0.548) (Heald et al, 1994; Gorochov
et al, 1995; Bernengo et al, 2001; Rappl et al, 2001; Scala
et al, 2002; Michel et al, 2003). These observations indicate
Figure 2
Comparison of Vb positive cells to other measures of blood tumor
burden. The median percentage (horizontal line) of Vbþ cells (67%) is
significantly higher than the median percentage of CD4þCD7 cells
(42%) and Se´zary cells (41%), but was not different than CD4þCD26
cells (53%). The box represents the 25th and 75th percentiles and the
error bars are the 10th and 90th percentiles.
Figure3
Correlation of Vb positive cells to CD4þCD7 or CD4þCD26
subsets. The percentage of Vbþ neoplastic cells correlates well with
the maximum percentage of CD4þCD7 or CD4þCD26 cells,
whichever is greatest (n¼30, r¼ 0.594, po0.001).
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that Se´zary cell counts are a poor measure of and often
underestimate blood tumor burden in patients with the le-
ukemic phase of CTCL.
Discussion
Our studies of leukemic phase CTCL with anti-Vb antibodies
indicate that Vb usage may be skewed toward Vb5, partic-
ularly Vb5.1. Of 32 Vb antibody-positive cases in this series,
the neoplastic cells from 9 (28%) reacted with the anti-
Vb5.1 clone IMMUN157, and 4 additional cases reacted
with anti-Vb5.2-3 clone MH3-2. Other frequently positive
reactions were to anti-Vb3.1, Vb12, and Vb13.6 (3 cases
each).
One must first consider whether the high frequency of
Vb5.1 could be a spurious result because of technical rea-
sons or a biased selection of patients. Although we do not
think this is likely, it is noted that the frequency of Vb5 usage
in our series (40%) was significantly higher than what has
been reported for leukemic CTCL in the literature (Fisher’s
exact test; p¼0.019). Nevertheless, in reported cases of
leukemic CTCL, Vb5 also was used more commonly than
other Vb segments (30 of 138 or 22%) followed by Vb8
(11%), Vb13 (11%), and Vb17 (7%) (Fig S1). Vb5.1 positivity
also was about twice as frequent as Vb5.2-3 in our patients,
but the ratio was equal in cases reported in the literature (13
cases bearing Vb5.1 vs 13 cases bearing Vb5.2 or Vb5.3
segments; four cases unknown); this difference was not
significant (exact w2 test, p¼ 0.233). Because certain anti-
Vb antibodies may react in a less restricted fashion, e.g., the
anti-Vb8 clone MX11 (Jack and Carrel, 1990), consideration
must also be given to the possibility that the anti-Vb5.1
clone IMMUN157 used in our studies was also prone to
inappropriate reactivity. We do not think this is likely be-
cause more Vb5.1þ cases reported in the literature reacted
to the anti-Vb5.1 clone LC4 than clone IMMUN157. At this
time molecular analysis of Vb usage are not available to
confirm these results.
Immunohistochemical studies on lesional skin of CTCL
have shown that a dominant neoplastic clone is often dif-
ficult to demonstrate with an anti-Vb antibody. Of 11 series
reported in the literature, (Jack and Carrel, 1990; O’Grady
et al, 1990; Ralfkiaer et al, 1991; Bagot et al, 1992; Bahler
et al, 1992; Boehncke et al, 1992; Gilks et al, 1992; Hunt
et al, 1992; McHenry et al, 1994; Finn et al, 1996; Potoczna
et al, 1996), a Vbþ clone was detected in lesional skin of
only 33 of 173 (19%) patients with MF and seven of 29
(24%) patients with SS. Most of these studies were, how-
ever, performed with a limited panel of 5 or 6 anti-Vb an-
tibodies that were available at the time, e.g., Vb3.1 (clone
8F10), Vb5a/5.2-3 (clone 1C1), Vb5b/5.3 (clone W112), Vb6a
(clone OT145), Vb8a (clone 16G8), and Vb12a (S511) from T
Cell Diagnostics, Woburn, MA. Anti-Vb5.1 antibody (clone
LC4) was included in the diagnostic panel in five of these
series (O’Grady et al, 1990; Bahler et al, 1992; Hunt et al,
1992; Finn et al, 1996; Potoczna et al, 1996), and only the
study of Potoczna et al (1996) used a broad panel of 21
antibodies that covered most of the T cell repertoire. One
study reported a high frequency of Vb8 restriction in nine of
16 cases of MF using clone MX11 (Jack and Carrel, 1990),
but to our knowledge such a restricted Vb repertoire was
never confirmed in other studies with this antibody nor with
different anti-Vb8 clones 16G8 or MX6. Another factor is
that the Vb antibody may not react appropriately to the Vb
segment. For example, Bahler et al (1992) found the ex-
pected positive antibody reaction in only three of nine cases
in which neoplastic cells were Vb5-, Vb6-, Vb8-, or Vb13-
positive by PCR analysis. False-negative reactivity to anti-
Vb antibodies also has been observed when neoplastic T
cells in the blood of SS were studied by flow cytometry
(Gorochov et al, 1995; Bigler et al, 1996). Thus, the low de-
tection rate of Vbþ clones in reported studies is related in
part to the limited number of available antibodies used in
the panel, the relatively low numbers of neoplastic cells in
minimally infiltrated lesional skin relative to the reactive cells
in the infiltrate, the failure of the particular antibody to react
appropriately to the Vb segment demonstrated by molec-
ular analysis, as well as failure of certain antibodies to react
using immunohistochemical techniques even when com-
bined with antigen retrieval.
Despite these confounding factors, of the reported 40 Vb
antibody-positive cases of MF/SS in the skin, reactivity
against Vb8 was by far the most frequently positive clone
(19 cases including nine cases reported by Jack and Carrel
(1990) followed by Vb5 (12 cases). If one considers only the
five series in which Vb5.1 antibody was included in the
screening panel (O’Grady et al, 1990; Bahler et al, 1992;
Hunt et al, 1992; Finn et al, 1996; Potoczna et al, 1996), then
a Vb5.1þ neoplastic clone was identified in eight of 21
(38%) of cases that reacted with an anti-Vb antibody. These
observations suggest that Vb5.1 usage may be more fre-
quent in lesional skin of CTCL than generally appreciated.
Conversely, molecular analysis of Vb expression in the skin
of MF/SS revealed only two Vb5.1þ clones in 37 cases
studied with multiple Vb family probes, and none of the 15
skin samples of SS were positive for Vb5 (Bahler et al, 1992;
Jackow et al, 1997; Thor Straten et al, 1998).
The reason for the apparent discrepancy in Vb frequen-
cies between immunohistochemistry and molecular genetic
analysis results on skin specimens and between skin and
blood samples is unclear. It seems conceivable that neo-
plastic T cells in advanced CTCL might lose surface mol-
ecules that are involved in homing into the skin such as
cutaneous lymphocyte antigen (CLA) and this would de-
crease the number of neoplastic cells in the skin relative to
the blood (Heald et al, 1993). Indeed Scala et al (2002) found
that CLA was expressed on only a minority of Vbþ neo-
plastic cells in the blood of patients with advanced SS. Al-
ternatively, Vb expression in the skin may be difficult to
assess because the density of neoplastic cells in the skin of
SS is often quite low compared with the non-neoplastic
reactive cell population that itself could show skewed Vb
usage due to the influence of bacterial SAg (Jackow et al,
1997).
Several possibilities might account for the observed in-
crease usage of Vb5.1 in CTCL. The first possibility is that
the frequent Vb5.1 usage simply reflects the fact that Vb5.1
is expressed to a greater degree by CD4þ than CD8þ T
cells (Grunewald et al, 1991; Geneve´e et al, 1994; Reed
et al, 1994; Shigematsu et al, 1996; van den Beemd et al,
2000) This, however, cannot be the entire explanation
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because Vb2 segments are expressed to an even greater
degree by CD4þ cells and these segments are infrequently
identified in leukemic CTCL. Another possibility is that
Vb5.1-bearing T cells may be inherently more prone to un-
dergo malignant transformation relative to other Vb families.
The V beta locus on the long arm of chromosome 7 at band
7q34 is rarely involved in CTCL, but an oncogenic virus
might conceivably use Vb5.1 sequence for entrance into the
cell. A third possibility to consider is whether neoplastic
Vb5.1þ T cells might be more responsive to mitogenic
stimulation in vivo than other Vb-bearing cells and therefore
more likely to expand and present as leukemic CTCL. Al-
though there is currently no evidence that this occurs, it
should be noted that Vbþ Se´zary cells can proliferate in
response to staphylococcal SAg via the relevant Vb seg-
ment (Tokura et al, 1992; Tokura et al, 1995). These obser-
vations demonstrate that staphylococcal proteins can
induce neoplastic cells to proliferate, and because keratin-
ocytes in CTCL express class II receptors (Tjernlund, 1981;
Stevens et al, 2003) proliferation of neoplastic T cells stim-
ulated by endotoxins that bind to the Vb5.1 segment could
occur in the skin microenvironment. Finally, there is clinical
evidence that the skin manifestations of SS can be amel-
iorated by topical or systemic antibiotic therapy (Tokura
et al, 1995; Jackow et al, 1997). A fourth possibility is that
microbial SAg (or antigen) might quantitatively affect the
pool of T cells from which a Vb5.1þ neoplastic emerges
when malignant transformation occurs. This possibility
seems to us to be more likely than the others and will be
developed as a hypothesis in some detail (Fig 4).
Hypothesis: bacterial superantigens play a selective
role in the development of CTCL Considerable evidence
has accumulated to indicate that microbial SAg can mod-
ulate Vb expression of T cells in the skin and play an im-
portant role in the pathogenesis of various skin diseases
(Skov and Baadsgaard, 2000; Yarwood et al, 2000). For ex-
ample, the skin of patients with AD is often colonized by
enterotoxin-producing strains of Staphylococcus aureus,
and these superantigenic toxins are capable of skewing the
Vb subfamily repertoire in skin-homing T cells as well as
increasing expression of the skin-homing receptor, CLA
(Leung et al, 1995; Neuber et al, 1996; Torres et al, 1998;
Dworzak et al, 1999; Strickland et al, 1999; Bunikowski et al,
2000; Davison et al, 2000; Skov et al, 2000; Zollner et al,
2000; Breuer et al, 2002). Even with healthy individuals,
molecular studies have shown differences in Vb family ex-
pression in skin samples compared with the blood, sug-
gesting an effect of the microenvironment of the T cell
repertoire (Dunn et al, 1993; Ahangari et al, 1996; Menssen
et al, 2000). Although these studies did not agree on which
Vb expression predominates in normal skin, Vb5 usage in
general and Vb5.1 in particular was underexpressed relative
to the blood. This observation indicates that CTCL is un-
likely to arise from the indigenous T cell population in
the skin.
Because some cases of CTCL are preceded by a chronic
dermatitis or AD (Rajka and Winkelmann, 1984; Abel et al,
1986; van Haselen et al, 1999), it seems plausible that the
increased usage of Vb5.1 in leukemic CTCL may be be-
cause neoplastic transformation is more likely to involve a
subset of Vb5.1þ skin-homing T cells that is more numer-
ous relative to other Vb segments. Perhaps bacterial SAg
play a role in the selection of Vb5.1 neoplastic clones. In this
regard, Linnemann et al (2004) recently characterized the
TCR g gene sequences of Vb5.1-expressing T cells isolated
from skin lesions of one patient with Vb5.1þ plaque phase
MF. About 60% of the of Vb5.1þ cells in the epidermis
belonged to the neoplastic clone whereas about 67% of the
Vb5.1þ cells in the dermis were different from the neo-
plastic clone and were polyclonal in origin. A staphylococcal
infection was also present, but details were not provided.
This study suggests that the neoplastic cells in this case
could have arisen from an increased number of polyclonal
Vb5.1-bearing T cells in the skin.
In support of the hypothesis that the number of Vb5.1þ
T cells is often increased in dermatitis such as AD, Potoczna
et al (1996) found Vb5.1 (clone LC4) expression by
immunohistochemistry to be common in eczematous skin
as well as CTCL. In addition, Torres observed a significantly
increased percentage of CLAþVb5.1þ T cells in children
with AD compared with normal controls (Torres et al, 1998).
Most other studies that evaluated the Vb repertoire in AD
have, however, not shown an increase in Vb5.1 in the skin
(Neuber et al, 1996; Yudate et al, 1996; Bunikowski et al,
2000), nor blood of AD patients (Strickland et al, 1999;
Bunikowski et al, 2000; Davison et al, 2000) compared to
normal controls, and Neuber et al (1996) actually found a
significantly decreased percentage of Vb5.1þ T cells in the
skin of AD. Therefore, it is possible but probably unlikely
that the predilection for neoplastic cells to express Vb5.1 in
leukemic CTCL is the result of malignant transformation of
normal skin-homing Vb5.1þ T cells that have expanded as
a result of the direct effect of bacterial SAg. The possibility
Figure 4
Bacterial superantigens might increase the frequency of Vb5 usage
in leukemic cutaneous T cell lymphoma via two hypothetic mech-
anisms. CD4þ skin-homing T cells expressing Vb5 segments, repre-
sented as a solid gray circle among other Vb segments, could
proliferate and expand in response to superantigenic stimulation rel-
ative to other T cells (panel A). Conversely, superantigen-sensitive Vb-
bearing cells such as Vb2, shown as a cross-hatched circle, could
undergo activation-induced apoptosis and depletion in response to
superantigenic stimulation, leaving behind a relative increase in Vb5
and other unresponsive T cells (panel B). When neoplastic transforma-
tion occurs, a relative increase of Vb5 usage would occur with either
model.
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of an antigen-specific expansion of Vb5.1þ cells cannot,
however, be excluded.
If staphylococcal or other microbial SAg play a significant
role in the selection of Vb usage in CTCL, then theoretically
this might occur as a result of either positive or negative
selection forces on skin-homing T cells. (Fig 4) With the
positive selection (expansion) model, exposure to microbial
SAg in vivo stimulates relevant Vb-bearing T cells to prolif-
erate, causing a polyclonal expansion of responsive cells
(Linnemann et al, 2004). To explain the increased usage of
Vb5.1 in CTCL, it is necessary to demonstrate that SAg
capable of stimulating T cells through Vb5.1 are often
present in the skin microflora and that Vb5.1-bearing T cells
are disproportionally expanded in such patients. With the
negative selection (deletion) model, the effect of the micro-
bial SAg might be to delete Vb-responsive T cells through
activation-induced apoptosis, leading behind a small pro-
portion of unresponsive (anergic) cells and T cells that bear
Vb segments unresponsive to the SAg. This model pre-
sumes that organisms capable of producing Vb5.1-stimu-
lating SAg would be less abundant on the skin compared
with other microorganisms that release SAg and that T cells
bearing Vb5.1 and other segments are increased in the skin
relative to T cells known to respond to SAg. Assuming that
neoplastic transformation occurs randomly within the skin-
homing T cell population, then the increased usage of Vb5.1
in CTCL could be explained with either model.
The most extensively studied staphylococcal toxins with
SAg capacity that colonize skin disorders like AD are the
staphylococcal enterotoxins A, B, C, and D (SEA–D) and
toxic shock toxin 1 (TSST-1). Toxin-producing strains are
isolated in 50%–65% of patients, and a single strain of S.
aureus may produce several toxins. Moreover, bacterial
SAg may stimulate T cells through more than one Vb seg-
ment. A compilation of enterotoxins produced by S. aureus
isolated from the skin lesions of AD from nine series in the
literature indicated that the frequency was highest for SEB
(32%) followed by SEA (26%), SEC (17%), TSST-1 (16%),
and SED (9%) (Hoeger et al, 1992; Leung et al, 1993;
McFadden et al, 1993; Akiyama et al, 1996; Nomura et al,
1999; Bunikowski et al, 2000; Zollner et al, 2000; Breuer
et al, 2002; Mempel et al, 2003). In terms of the major Vb
families expressed by normal peripheral T cells, TSST-1 can
stimulate Vb2-bearing cells, SEC3 can weakly stimulate
Vb5.1-bearing cells, SEC2 and SEC3 can stimulate Vb13.1-
3-bearing cells, and SEB and SEC2 can stimulate Vb17-
bearing cells (Kotzin et al, 1993; Leung et al, 1995; Davison
et al, 2000; Petersson et al, 2003; Proft and Fraser, 2003).
It therefore seems unlikely that any of these common
staphylococcal SAg play much of a role in a positive se-
lection of Vb usage in CTCL. Vb5.1-bearing T cells may,
however, be activated by SEE, which also stimulates Vb8þ
T cells, as well as by several members of a recently char-
acterized toxin-producing staphylococcal family associated
with the enterotoxin gene cluster (e.g., SE I, K, L, and Q) that
has been identified on nearly 50% of isolates from AD (Or-
win et al, 2001; Orwin et al, 2002; Mempel et al, 2003; Orwin
et al, 2003). Furthermore, some species of Streptococcus
pyogenes and Candida albicans produce SAg capable of
stimulating Vb5.1-bearing T cells (Walsh et al, 1996; Proft
and Fraser, 2003). Therefore, the microflora in CTCL could
potentially harbor organisms that could expand Vb5.1þ T
cells prior to neoplastic transformation, but direct evidence
for this is currently lacking.
Jackow et al (1997) correlated bacterial toxin production
by S. aureus and Vb usage in CTCL including 14 patients
with SS. The toxins produced by these organisms were
characterized in 16 isolates, and in nine cases more than
one toxin with superantigenic activity was identified, a result
similar to patients with AD. Six isolates had evidence of
TSST-1, and the authors correlated this to overexpansion of
Vb2þ T cells in the skin and/or blood. It seems possible
that the Vb2þ cells in these cases represented a polyclonal
expansion of reactive cells rather than an expanded neo-
plastic population. It also should be noted that Vb expres-
sion in skin from healthy controls often achieved similar
levels of expression, rendering interpretation of these re-
sults problematic (Musette and Bachelez, 1997). Neverthe-
less, this study provides no evidence that Vb5þ T cells are
preferentially expanded in the lesional skin of CTCL.
A major argument against the SAg-mediated positive
selection hypothesis as stated above is the fact that Vb
usage by neoplastic cells is not increased for Vb segments
that are stimulated by commonly occurring staphylococcal
SAg, e.g., Vb2 via the action of TSST-1 or Vb3 or Vb17 via
the action of SEB, etc. In fact, considering that Vb2 is one of
the most frequently expressed Vb segments by normal
blood T cells and that Vb2 stimulation by TSST-1 occurs in
AD, it is surprising that Vb2 is not expressed at a higher
frequency in leukemic CTCL. In addition, if a SAg were im-
plicated in a polyclonal expansion of responsive T cells in
CTCL prior to malignant transformation as suggested by the
work of Linnemann et al (2004), then there might also be an
increase in CD8 cells bearing the same Vb segment as the
neoplastic cells. In this regard, Lima et al (2003) observed
one or more expansions of a Vb segment for CD8þ T cells
in 14 of 16 patients with a CD4þVbþ SS. In three cases
where analysis of Vb expression was performed on both the
neoplastic CD4þ and normal CD8þ cells, the Vb usage
differed between the subsets. This finding argues against
the positive selection model by SAg. It should, however, be
noted that the effect of bacterial SAg on CD8þ cells is less
profound than on CD4þ cells and this could produce a dif-
ferential effect on Vb usage in vivo (Kawabe and Ochi, 1991).
The alternative hypothesis, i.e., the negative selection
by SAg prior to neoplastic transformation, proposes that
chronic exposure to these microbial SAg might act to de-
plete T cells bearing Vb2, Vb, or Vb17, accounting for the
unexpectedly low frequency of usage of these Vb segments
in CTCL, and because Vb5.1 is not affected by TSST-1 and
SEA-D, subsequent malignant transformation would be
more often involve unaffected Vb5.1þ cells. This would
explain the disproportionately high frequency of V5.1 vis-a`-
vis Vb2.
Support for this hypothesis comes from studies in mice
that were injected with SE. Single doses result in an initial
rise in the proportion of reactive Vb cells followed by a dra-
matic decline, mediated mostly by Fas–FasL-induced
apoptosis (McCormack et al, 1993). If administered repeat-
edly in low doses, almost total depletion of target cells oc-
curred in the absence of apparent prior proliferation.
Recovery gradually occurred from newly generated cells
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in the thymus in the absence of enterotoxin, and a propor-
tion of the target Vbþ cells became anergic to further
stimulation. Some T cells are activated by the SAg in an
antigen-specific manner, and repetitive stimulation may
eventually result in T cell oligoclonality (Kim et al, 2003). In
humans, repeated ligation of the TCR or SAg also results in
activation-induced cell death (Weber et al, 2000). In AD,
which serves as a paradigm for the effect of the microbial
SAg on skin-homing T cells, a high percentage of CLAþ
CD45ROþ T cells in the peripheral blood are activated and
undergoing apoptosis compared with normal controls (Yo-
shino et al, 2000; Akdis et al, 2003). T cells with a TH2
cytokine profile were more resistant to undergoing apopto-
sis than TH1 cells (Akdis et al, 2003). It is therefore con-
ceivable that chronic exposure to one or more bacterial SAg
in the skin may ultimately deplete responsive Vbþ cells
analogous to what is observed in mice.
Recently, blood samples from patients with CTCL have
been analyzed by complementarity determining region 3
(CDR3) length spectratyping, also known as immunoscopy
(Ingen-Housz-Oro et al, 2002; Yawalkar et al, 2003). This is
an RT-PCR-based method that is semi-quantitative and
highly sensitive. A recent study with the immunoscope
technique on patients with CTCL without overt blood in-
volvement (all with blood CD4/CD8 ratios less than 10)
showed multiple monoclonal and oligoclonal CDR3 spec-
tratype patterns as well as loss of other Vb families including
patients with early disease (Yawalkar et al, 2003). These re-
sults suggest a global assault on the T cell repertoire across
multiple Vb families reminiscent of spectratypes found in
advanced human deficiency disease. Although human T cell
lymphotropic virus type I has been linked to CTCL (Pancake
et al, 1995), and this potentially could account for the find-
ings by immunoscopy, it seems possible that sustained su-
perantigenic stimulation of sensitive T cell populations by a
microbial antigen might also cause depletion of such cells in
the blood. Further investigations on conditions like AD are
needed to evaluate this hypothesis.
If a microbial SAg is involved in depleting part of the Vb
repertoire of skin-homing T cells prior to neoplastic trans-
formation, then this could also explain the association of
CTCL with both HLA class I molecules, e.g., HLA-B8 (Dick
and Mackie, 1977; Rosen et al, 1985), and class II mole-
cules, i.e., HLA-DR (DRB111), and HLA-DQB103 alleles in
MF and SS (Jackow et al, 1996; Hodak et al, 2001) as well
as HLA-DQB10502 in SS (Jackow et al, 1996). The asso-
ciation with class I HLA alleles and infectious disease have
been demonstrated mainly with HLA-B (Cooke and Hill,
2001), and interactions between class I and class II may
contribute to disease susceptibility (Harbo et al, 2004). It is
tempting to speculate that the expression of a particular
HLA phenotype on epidermal cells of patients with CTCL
might excessively influence the T cell response to staphy-
lococcal SAg through Vb sequences as has been reported
for streptococcal SAg (Kotb et al, 2003).
The possibility that antigenic rather than superantigenic
stimulation is responsible for the increase in Vb5.1 usage
must also be considered. This possibility can be addressed
by sequencing the CDR3 of the TCR to determine if there is
a preferential use of any BJ segment for Vb5.1þ cells. In
this regard, however, Ingen-Housz-Oro et al (2002) found no
common CDR3 motif was found among samples from 15
patients with SS.
The clinical implications of these observations suggest
that the Vb5.1 segment might be selected as a target for
initial immunotherapy studies using naked DNA vaccination
or dendritic cell immunotherapy (Reddy et al, 2001). In ad-
dition, cytotoxic immune responses against TCR Vb
epitopes that were induced using V-region-derived pep-
tides from neoplastic CTCL cells have been demonstrated
in vitro (Winter et al, 2003), and the therapeutic effect of
extracorporeal photopheresis is mediated in part by an anti-
clonotypic response against the Vb segment of the TCR
(Berger et al, 1998). Further studies that target Vb5.1 for
immunotherapy would be worthwhile.
Materials and Methods
Forty-nine patients with the leukemic phase of CTCL (19 men, 30
women; median age, 69 y; range, 41–87) were evaluated one by of
us (E. C. V.) at Hahnemann University (now Drexel University Col-
lege of Medicine) between 1987 and 2000. Blood samples were
obtained and stored with the informed consent of the donor and in
accordance with the Declaration of Helsinki protocol. The Institu-
tional Review Board of Hahnemann University approved all
described studies.
Statistical analysis The difference in median values for laboratory
studies was tested using the nonparametric Mann–Whitney test.
The correlation between the percentage of Vbþ cells and other
measures of blood tumor burden was examined using the Spear-
man rank order correlation test. Fisher’s exact test and Pearson w2
test for 2  2 tables and R  C tables, respectively, were used as
measures of association among categorized laboratory parame-
ters. The mean percentages of Vb expression on normal CD4þ
cells as determined by anti-Vb antibodies in the IO Test Beta Mark
kit was provided by Beckman Coulter (Fullerton, California).
Statistical software used for data analysis was SigmaStat for
Windows, Version 3 (Jandel Scientific Software, San Rafael, Cal-
ifornia), and StatXact-3 (CYTEL Software Corporation, Cambridge,
Massachusetts).
Previous observations Initial flow cytometry studies by our group
were performed during in the mid-1990s using a limited panel of
anti-TCR Vb antibodies that were obtained from T Cell Diagnostics
(Woburn, Massachusetts) [Vb5a/5.2-3 (1C1), Vb5b/5.3 (W112),
Vb5c/5.1 (LC4), Vb6.7 (OT145), Vb8a (16G8), Vb12 (S511), as well
as Va2 (F1)], and Immunotech (Westbrook, Maine) [Vb3 (LE-89),
Vb14 (CAS1.1.3), Vb18 (BA62.6), and Vb20 (ELL1.4)]. Of 17 patients
with SS and a documented Vb-positive clone byRT-PCR, ten ex-
pressed a TCR Vb segment for which a corresponding anti-Vb
monoclonal antibody was available to test for reactivity. The Vb
usage by the neoplastic cells was confirmed with the anti-Vb an-
tibody in seven of these cases, whereas the neoplastic cells failed
to react in three cases (Bigler et al, 1996). This work showed that
some anti-Vb antibodies fail to react appropriately with cells that
have the corresponding Vb segment (false-negative reactions), a
finding also observed by others (Gorochov et al, 1995). In this re-
gard, the neoplastic cells of one patient that did not react with the
anti-Vb3 clone LE-89 in the previous screening panel was found in
the present study to react with the anti-Vb3 clone CH92. Moreover,
subsequent studies (unpublished) of five additional Se´zary patients
with a Vb-positive clone by RT-PCR identified two patients whose
neoplastic cells displayed a discordant anti-Vb antibody reactivity:
one Vb18 by PCR and Vb13 by antibody and the other Vb14 by
PCR and Vb5.1 by antibody. The other 3 patients were studied by
molecular methods only and expressed Vb13.1, Vb22, and Vb13.2.
The available information from these early studies is incorporated
into Tables S1 and S2 and Fig S1.
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Additional observations Additional characterization of neoplastic
cells of CTCL with a large panel of anti-Vb antibodies was per-
formed in the flow cytometry laboratory at Hahnemann University
between 1999 and 2001. The goal was to identify cases of Vb-
positive leukemic phase CTCL in our tissue bank that could be
used for additional studies with other monoclonal antibodies.
Cryopreserved peripheral blood lymphocytes from 47 patients with
documented blood involvement were studied with monoclonal an-
tibodies for expression of T cell markers (CD3, CD4, CD7, CD8,
CD26) and TCR Vb expression using a panel of 20 antibodies
conjugated with fluorescein isothiocyanate purchased from Beck-
man Coulter: TCR Vb1.1-2 (BL37.2), Vb2 (MPB2D5), Vb3 (CH92),
Vb5.1 (IMMU157), Vb5.2 (36213), Vb7.1 (ZO´E), Vb8.1-2 (56C5.2),
Vb11 (C21), Vb12 (VER2.32.1), Vb13.1 (IMMUN222), Vb13.6 (JU74.3),
Vb14 (CAS1.1.3), Vb16 (TAMAYA1.2), Vb17 (E17.5F3.15.13), Vb20
(ELL1.4), Vb21.3 (IG125), Vb22 (IMMUN546), and BD PharMingen
(San Diego, California): Vb5.2-3 (MH3-2), Vb9 (AMKB1-2), and
Vb23 (AHUT7). To clarify results, additional staining of selective
cases was performed with antibodies Vb5a (1C1), Vb5b (W112),
and Vb5c (LC4) from BD PharMingen that react against segments
Vb5.2-3, Vb5.3, and Vb5.1, respectively. The gate for lymphocytes
was based on light scatter, including large lymphocytes when
present, and if necessary verified with CD45 and CD14. The per-
centage of all CD3þ , CD3þCD4þ , CD3þCD8þ , CD4þCD7,
CD4þCD26, and all Vbþ cells within the lymphocyte gate was
recorded (Table S1).
The complete panel was run on samples from 42 patients in-
cluding 12 of 19 patients studied earlier with a different Vb antibody
panel as well as six of 10 patients that were previously reported
(Table S1, Groups 1–3). In addition, a limited number of Vb anti-
bodies were run on 6 patients with a previously identified Vb an-
tibody positive clone as well as a patient with coexisting B-cell
chronic lymphocytic leukemia (Table S1, additional cases). At the
time of sampling, 46 patients were diagnosed to have SS (gener-
alized erythroderma with leukemic blood involvement), and in eight
of these patients, the SS had been preceded by the diagnosis of
MF. The other three patients had the cutaneous manifestations of
extensive plaque or tumor phase MF. To confirm or clarify uncertain
results, the antibody panel was repeated on separate samples
from 5 patients (data not shown).
According to the criteria proposed by the International Society
for Cutaneous Lymphoma (Vonderheid et al, 2002), all patients ful-
filled at least one of the hematologic criteria for leukemic involve-
ment (B2 blood rating). Specifically, 31 patients had an absolute
Se´zary cell count of 1.0 K per mL or more, 35 patients had an
increase in CD4þ cells resulting in a CD4/CD8 ratio of ten or more,
41 patients had evidence of a chromosomally abnormal clone in
the blood, and 23 patients had relative or absolute lymphocytosis
with molecular evidence of a dominant T cell clone. Altogether one
criterion was present in nine patients, two criteria were present in
11 patients, three criteria were present in 12 patients, and all four
criteria were present in 16 patients. The only patient without any of
these criteria was a patient with SS who had been heavily pre-
treated with suppression of blood lymphocyte counts, but with
45% Se´zary cells per 100 lymphocytes on smears. Two patients
had a CD4/CD8 ratio exceeding 10, but without an increase in
CD4þ cells: one patient had SS with coexisting B-cell chronic
lymphocytic leukemia, the other patient only had a depressed CD8
count. In addition, many of the cases had evidence of pheno-
typically abnormal T cells by flow cytometry, and an increased
percentage of CD4þCD7 or CD4þCD26 subsets in the
lymphocyte gate of 40% and 30% or more (ISCL tentative crite-
ria for leukemic involvement) (Bernengo et al, 2001; Vonderheid
et al, 2002; Vonderheid and Bernengo, 2003), was found in 23 and
34 patients, respectively.
Literature review The literature was reviewed for cases of le-
ukemic CTCL in which the neoplastic cells in the blood were char-
acterized for Vb expression using various methods (Table S2). An
effort was made to avoid counting cases more than once. A total of
136 cases were identified (Table S2; Fig S1). Vb5 usage was iden-
tified in 30 (22%) of the cases followed by Vb8 and Vb13 (each
11%). When Vb5 expression was further characterized into sub-
families, 13 of 26 (50%) cases that were studied expressed Vb5.1.
Of interest, biclonal expression of Vb1/Vb14 and Vb10/Vb18 was
observed in two cases of SS studied by Bahler (not counted in the
review) (Bahler et al, 1992).
Studies supported by the Leonard and Ruth Levine Skin Research
Fund.
Supplementary Material
The following material is available from http://www.blackwellpublishing.
com/products/journals/suppmat/JID/JID23586/JID23586sm.htm
Figure S1
Vb5 expression in leukemic CTCL is increased relative to other Vb
segments.
Figure S2
The percentage of Vbþ neoplastic cells correlates significantly but
weakly with the percentage of CD4þCD7 (panel A) but not
CD4þCD26 (panel B) in this series.
Table S1. Patients with leukemic cutaneous T cell lymphoma studied
with anti-Vb antibodies.
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